Pfiz­er launch­es re­bate pro­gram for rare dis­ease pa­tients who have to stop tak­ing Panzy­ga

Pfiz­er is launch­ing its sec­ond-ever re­bate pro­gram, this time for Panzy­ga, its treat­ment for a rare neu­ro­log­i­cal dis­ease of the pe­riph­er­al nerves.

The pro­gram be­gan last month, ac­cord­ing to STAT which first re­port­ed the news, and of­fers a re­fund of out-of-pock­et costs for pa­tients who must dis­con­tin­ue their course be­fore the fifth treat­ment for “clin­i­cal rea­sons.”

Panzy­ga was ap­proved back in 2018 to treat pri­ma­ry im­mun­od­e­fi­cien­cy (PI) in pa­tients two years and old­er and chron­ic im­mune throm­bo­cy­tope­nia (cITP) in adults. It has since picked up an in­di­ca­tion in chron­ic in­flam­ma­to­ry de­myeli­nat­ing polyneu­ropa­thy (CIDP), a con­di­tion that’s char­ac­ter­ized by weak­ness of the arms or legs, tin­gling or numb­ness, and a loss of deep ten­don re­flex­es, ac­cord­ing to the NIH.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.